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Background and Purpose: Elevated sympathetic nervous system (SNS) activity is
a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ
damage and cardiovascular risk. In this study we examined whether baseline metabolic
status influences the degree of sympathoinhibition attained following equivalent dietary
weight loss.
Methods: Un-medicated obese individuals categorized as normal glucose tolerant
(NGT, n = 15), impaired glucose tolerant (IGT, n = 24), and newly-diagnosed T2D
(n = 15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for
4-months. The three groups were matched for baseline age (56 ± 1 years), body
mass index (BMI, 32.9 ± 0.7 kg/m2), and gender. Clinical measurements included
whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by
microneurography), spontaneous cardiac baroreflex sensitivity (BRS), and oral glucose
tolerance test.
Results: Weight loss averaged −7.5 ± 0.8, −8.1 ± 0.5, and −8.0 ± 0.9% of
body weight in NGT, IGT, and T2D groups, respectively. T2D subjects had significantly
greater reductions in fasting glucose, 2-h glucose and glucose area under the curve
(AUC0−120) compared to NGT and IGT (group effect, P < 0.001). Insulinogenic index
decreased in IGT and NGT groups and increased in T2D (group × time, P = 0.04).
The magnitude of reduction in MSNA (−7 ± 3, −8 ± 4, −15 ± 4 burst/100 hb,
respectively) and whole-body norepinephrine spillover rate (−28 ± 8, −18 ± 6,
and −25 ± 7%, respectively), time effect both P < 0.001, did not differ between groups.
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After adjustment for age and change in body weight, 1 insulin AUC0−120 was
independently associated with reduction in arterial norepinephrine concentration, whilst
1 LDL-cholesterol and improvement in BRS were independently associated with
decrease in MSNA.
Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar
sympathoinhibition in matched obese subjects with different baseline glucose tolerance.
Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is
associated with reduction in SNS activity following weight loss intervention.
Keywords: sympathetic nervous system, obesity, weight loss, hypocaloric diet, glucose tolerance,
hyperinsulinemia, type 2 diabetes
INTRODUCTION
The high prevalence of obesity, estimated to exceed 25% in many
developed countries including Australia (Australian Bureau
of Statistics, 2015), is a serious public-health concern that
confers excess mortality and morbidity due to its associations
with chronic conditions such as type 2 diabetes (T2D) and
cardiovascular disease (Prospective Studies Collaboration, 2009).
It is therefore pertinent to elucidate potential mechanisms that
link excess adiposity to cardiometabolic risk and to identify
groups most likely to benefit from targeted lifestyle interventions.
The sympathetic nervous system (SNS) plays a pivotal role in
both cardiovascular and metabolic regulation and perturbations
in SNS activity are widely believed to contribute to the
pathophysiology of the obese state. An early viewpoint, based on
experimental hypothalamic models of obesity, clinical studies of
venous and urinary norepinephrine concentration, and studies
in Pima Indians (an ethnic population with low SNS activity)
was that SNS underactivity was the basis of weight gain and the
development obesity (Bray, 1990; Tataranni et al., 1997; Snitker
et al., 2000). This was congruent with the known importance of
the SNS in all aspects of daily energy expenditure. However, more
recent studies which have applied more specific techniques such
as direct microneurographic recordings of efferent sympathetic
nerve traffic and isotope dilution, indicate that obesity is a state of
chronic sympathetic overactivity and that there is organ specific
differentiation in sympathetic outflow favoring skeletal muscle
vasculature and the kidneys (Vaz et al., 1997; Grassi et al., 2004,
2005). Elevated SNS activity and impaired baroreflex sensitivity
(BRS) is evidenced in obese, metabolic syndrome, and T2D
cohorts when compared to lean controls (Lee et al., 2001; Huggett
et al., 2003; Grassi et al., 2005) and the greater contribution
of visceral, as opposed to subcutaneous fat accumulation, to
sympathetic neural drive has been affirmed (Alvarez et al., 2002;
Grassi et al., 2004).
Prospective epidemiological and offspring studies provide
information on the chronology of pathogenic changes in
the general and at risk populations. Various indices of SNS
activity (baseline venous norepinephrine concentration, the
norepinephrine response to cold pressor test, and resting heart
rate) have been positively associated with future weight gain,
insulin resistance and hyperglycemia in epidemiological studies
with 5–18 years follow-up (Masuo et al., 2003; Flaa et al., 2008;
Wulsin et al., 2015). Although seemingly counterintuitive,
elevated SNS activity could predispose to weight gain via
β-adrenoceptor desensitization and the promotion of central
insulin resistance (Vollenweider et al., 1994; Julius et al.,
2000). Notably, insulin-sensitive off-spring of T2D patients
have elevated single-unit and multi-unit muscle sympathetic
nerve activity (MSNA) compared with age- and body mass
index (BMI)-matched controls with no family history of T2D
(Huggett et al., 2006). This finding highlights that sympathetic
overactivity is an early pathogenic phenomenon in subjects
genetically predisposed to the development of metabolic
disease. In established obesity several factors act in concert to
maintain elevated sympathetic drive including hyperinsulinemia,
obstructive sleep apnoea, baroreflex impairment, and activation
of the renin-angiotensin system (Lambert et al., 2010).
Sustained sympathetic activation is mechanistically involved
in obesity-related target organ damage such as left ventricular
diastolic dysfunction, left ventricular hypertrophy, and arterial
remodeling via both blood pressure-mediated and blood
pressure-independent effects (Schlaich et al., 2009). Vis-a-vis,
plasma norepinephrine is an independent predictor of adverse
cerebral and cardiovascular events (Yufu et al., 2014).
Weight loss through energy-restricted diet and/or physical
activity represents first-line treatment for obesity and has
proven sympathoinhibitory benefits (Straznicky et al., 2010).
However, relatively little attention has focused on whether
baseline metabolic status modifies the magnitude of change
in SNS activity following weight reduction. Our group has
previously demonstrated that hyperinsulinemic subjects derive
significantly greater sympathoinhibition than normoinsulinemic
subjects at matched weight loss (Straznicky et al., 2014). This
concurs with the known central sympathoexcitatory effects of
insulin (Anderson et al., 1991; Rahmouni et al., 2004). Other
studies have shown greater improvement in glycemic and
cardiac autonomic indices in T2D subjects compared to normal
glucose tolerant (NGT) subjects after lifestyle induced and
surgical weight loss (Solomon et al., 2010; Casellini et al., 2016).
Hitherto, the relative benefits of weight loss in obese subjects
with different stages of glycemic control on robust assessments
of SNS activity are unknown. Moreover, there are no data
regarding the effects of weight loss on MSNA or norepinephrine
kinetics in T2D populations. The present study was conducted
to compare the impact of 4-month hypocaloric diet (HCD) on
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direct recordings of efferent postganglionic MSNA and whole-
body norepinephrine kinetics in obese subjects categorized as
NGT, impaired glucose tolerant (IGT) and newly diagnosed
T2D. We hypothesized that T2D subjects would derive the
greatest sympathoinhibition at equivalent weight loss due to
greater attenuation of glycemia and concomitant improvement
in baroreflex function (Gerritsen et al., 2000).
METHODS
Subjects
Data were pooled from three weight loss trials conducted in our
laboratory (NCT01771042, NCT00163943, and Straznicky et al.,
2005). Entry criteria, dietary intervention, and experimental
methodologies were identical across the trials. Study participants
were recruited from newspaper advertisements on the basis
of being a non-smoker, aged 45–65 years, with a BMI
> 27 kg/m2 and weight stable (±1 kg) in the previous 6
months. Females were post-menopausal. Exclusion criteria
comprised history of cardiovascular, cerebrovascular, renal, liver,
or thyroid diseases; use of continuous positive airway pressure
treatment; and consumption of medications that could affect
study parameters (e.g., oral hypoglycemics, cholesterol-lowering,
anti-hypertensive, anti-depressant, and hormone replacement
therapies). Screening tests were performed over 2 visits 1 week
apart. At the first visit written informed consent was obtained and
participants’ medical and dietary histories were recorded. Clinical
testing included an electrocardiogram, fasting biochemistry (urea
and electrolytes, liver function tests, and lipids), and supine
resting blood pressure, measured as the average of 5 readings after
5 min rest using a Dinamap monitor (Model 1846SX, Critikon
Inc., Tampa, FL, USA). Body weight was measured in indoor
clothes without shoes, using a digital scale. Waist circumference
was measured at its smallest girth and hip circumference at the
level of the greater trochanters. Subjects were then given a 4-day
prospective diet and exercise diary to be returned the following
week. At the second screening visit, diet and exercise records were
reviewed, subjects received a physical examination by the study
doctor and blood pressure measurements were repeated. Clinical
investigations were performed at baseline and after 16-weeks of
HCD. The project was approved by the Alfred Hospital Human
Research Ethics Committee (ID 1/13).
Dietary Intervention
Habitual dietary intake was assessed by 4-day prospective diet
records using Australian food composition tables (Foodworks 7
Professional, Xyris Software, Kenmore Hills Qld 4069). Subjects
were prescribed HCD at 25% energy deficit using a modified
Dietary Approach to Stop Hypertension (DASH) eating plan
(Appel et al., 1997), with higher protein and lower carbohydrate
content (25% protein, 30% fat, and 45% carbohydrate) to
maximize fat loss (Layman et al., 2003). The DASH diet has
an emphasis on fruits, vegetables, nuts, legumes, wholegrain
cereals, low-fat dairy foods and lean red meat, fish and poultry.
Olive oil and polyunsaturated margarine were the major fat
sources. Previous studies have demonstrated that adherence
to a DASH dietary pattern during lifestyle intervention is
accompanied by beneficial changes in blood pressure, lipid
profile and homeostasis model assessment of insulin resistance
(HOMA-IR) which are attributed to both weight loss and weight
loss-independent effects (Appel et al., 1997; Lien et al., 2007).
Participants were provided with written dietary instructions,
14-day menu plans and recipes, and prepared food in their
home environment. They attended fortnightly for body weight
measurement and dietary counseling with the study dietician.
With regards to exercise they were instructed to walk briskly for
30 min, at least 5 days per week, in accordance with the American
Diabetes Association Position Statement (Inzucchi et al., 2012).
Dietary intake and exercise level was monitored by prospective
4-day records.
Clinical Investigations
Assessments of SNS activity, BRS and oral glucose tolerance
were performed together on the samemorning. Subjects attended
for clinical testing at 8 a.m. after an overnight fast and having
abstained from alcohol and heavy exercise for 36 h and caffeine
for 18 h. All experiments were carried out in the supine position
in a temperature controlled (22◦C) research room. Subjects
voided prior to commencement.
Whole-Body Norepinephrine Kinetics
The dynamic processes of whole-body norepinephrine entry
or “spillover” into and removal from the central plasma
compartment, were determined under fasting conditions using
the isotope dilution method (Esler et al., 1979). This technique
involves the intravenous infusion of [3H]-norepinephrine and
measurement of norepinephrine specific activity and endogenous
norepinephrine in arterial blood, sampled from the brachial
artery, under steady-state conditions. After a priming bolus
of 2.36 µCi of 1-[ring-2,5,6-3H]-norepinephrine (Perkin-Elmer,
Waltham, MA, US; specific activity, 10–30 µCi/mmol), an
infusion was commenced at 0.24µCi×min−1, with arterial blood
sampling 30 min after infusion commencement. The following
calculations were performed:
Norepinephrine clearance (L/min) =
[
3H
]
− norepinephrine infusion rate
(
dpm/min
)
[
3H
]
− norepinephrine plasma concentration
(
dpm/ml
)
× 1000
Norepinephrine spillover
(
ng/min
)
=
plasma norepinephrine
(
pg/ml
)
× clearance
(
ml/min
)
1000
Muscle Sympathetic Nerve Activity
Recordings of fasting multi-unit postganglionic MSNA were
made from a tungsten microelectrode (FHC, Bowdoinham,
ME, USA) inserted into the right peroneal nerve at the
fibular head (Vallbo et al., 2004). A subcutaneous reference
electrode was positioned 2–3 cm away from the recording site.
Standard criteria were used to ascertain a MSNA site. The
nerve signal was amplified (X50,000), filtered (bandpass, 700–
2000 Hz), and integrated. Intra-arterial blood pressure, ECG,
respiration, and MSNA were digitized with a sampling frequency
of 1000 Hz (PowerLab recording system, model ML 785/8SP,
ADI Instruments). Resting measurements were recorded over a
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15-min period and averaged. Sympathetic bursts were counted
manually and expressed as burst frequency (bursts/min) and
burst incidence (bursts/100 heart beats).
Cardiac Baroreflex Sensitivity
Spontaneous cardiac BRS was assessed by the sequence method
(Parati et al., 2004). The slope of the regression line between
cardiac interval and systolic blood pressure was calculated for
validated sequences of three or more consecutive heartbeats in
which systolic blood pressure progressively increased and cardiac
interval lengthened (type 1 sequence) or systolic blood pressure
progressively decreased and cardiac interval shortened (type 2
sequence), with a lag of 1 beat. Recordings were averaged over
a 15-min period of supine rest.
Metabolic and Biochemical Measurements
After completion of norepinephrine kinetic and
microneurographic measurements subjects underwent a
standard OGTT. It is of note that high specific activity [3H]-
norepinephrine has no physiological effects at the doses used
(Esler et al., 1979). A 2-h 75-g oral glucose tolerance test (OGTT,
Glucaid, Fronine PTY, LTD, Taren Point, NSW 2229, Australia)
was administered with 30-min intravenous blood sampling for
determination of glucose and insulin responses (area under the
curve, AUC0−120) using the trapezoidal rule. Homeostasis model
assessment-insulin resistance (HOMA-IR) and the Matsuda
insulin sensitivity index (ISI) were calculated as indices of
insulin resistance and sensitivity, respectively (Matthews et al.,
1985; Matsuda and DeFronzo, 1999). The insulinogenic index
(1 insulin 0–30 min divided by 1 glucose 0–30min) was
used to assess pancreatic β-cell function. Categorization was
based on WHO diagnostic criteria (World Health Organization,
2006): T2D, fasting plasma glucose ≥7.0 mmol/L or 2-h plasma
glucose ≥11.1 mmol/L; IGT, fasting plasma glucose <7.0
mmol/L and 2-h plasma glucose ≥7.8 and <11.1 mmol/L; NGT,
2-h plasma glucose <7.8 mmol/L. Supine fasting blood samples
were obtained for measurement of lipid profile, non-esterified
fatty acids (NEFAs), high sensitivity C-reactive protein (hs-CRP),
leptin, and plasma renin activity (PRA).
Laboratory Assays
Plasma glucose and lipid profile were measured on a
commercial analytical system (Architect C18000 analyzer,
Abbott Laboratories, Illinois, USA). High sensitivity C-reactive
protein (hs-CRP) was quantified by immunoturbidimetric
assay, insulin, leptin, and PRA by radio-immuno assay
(Linco Research, Inc., Missouri, USA; REN-CT2, CIS bio
international, France) and NEFA by enzymatic colorimetry
(Wako Pure Chemical Industries, Ltd, Osaka, Japan). These
assays were performed in duplicate. Plasma norepinephrine
was assayed by high performance liquid chromatography with
electrochemical detection, following extraction by alumina
adsorption. [3H]-norepinephrine was assayed by liquid
scintillation chromatography and corrected for loss during
extraction using recoveries of internal standard. Intra-assay
CVs in our laboratory are 1.3% for norepinephrine and 2.3%
for [3H]-norepinephrine; inter-assay CVs are 3.8 and 4.5%,
respectively.
Statistical Analyses
Statistical analysis was performed using SigmaStat Version 3.5
(Systat Software Inc., Point Richmond, CA, USA). Data are
presented as the mean ± SEM. Baseline parameters in the
three study groups were compared by one-way ANOVA and
Kruskal-Wallis one-way ANOVA on ranks. Two-way repeat
measures ANOVA was used to test for group effects, time effects
and group × time interactions, with the Holm-Sidak test for
multiple post-hoc comparisons. Non-parametric data were log
transformed. Post-intervention changes in study parameters (1)
were compared by one-way ANOVA and one-way ANOVA
on ranks as appropriate. Sub-group analysis according to
baseline hyperinsulinemia (defined as insulin AUC0−120 >
9500mU · min · L−1, the median value in the cohort) was
performed by 2-way ANOVA. Univariate associations between
change in SNS activity and other variables were assessed
using Pearson’s correlations in the pooled data set. Forward
stepwise linear regression analysis, adjusted for age and change
in body weight, was performed to identify the independent
predictors of change SNS parameters. Variables with P ≤ 0.05
in univariate analyses were entered into the regression model.
Statistical significance was accepted at the P < 0.05 (two-tailed)
level.
RESULTS
Subjects
Table 1 presents baseline demographic, anthropometric, and
clinical data of the study participants. The groups were matched
for age, BMI, lipid profile, and clinic blood pressure. Each
group exercised for ∼30 min per day, primarily in the form of
walking. In accordance with the categorization, T2D subjects
had higher fasting glucose, 2-h glucose, glucose AUC0−120 and
HOMA-IR and lower insulinogenic index compared to NGT and
IGT groups. The insulin response to OGTT was greatest in the
NGT, albeit differences between groups did not reach statistical
significance (P = 0.12). Baseline measures of SNS activity
did not differ between study groups. Arterial norepinephrine
concentration averaged 333 ± 49, 274 ± 24, and 258 ± 25
pg/ml in NGT, IGT, and T2D groups, respectively (P = 0.35).
Corresponding values for whole-body norepinephrine spillover
rate were 701 ± 95, 625 ± 68, and 563 ± 76 ng/min (P = 0.42)
and MSNA burst incidence were 63 ± 5, 65 ± 3 and 64 ± 4
bursts/100 hb (P = 0.93).
Anthropometrics and Dietary Intake
Weight loss averaged −7.9 ± 0.4% of body weight overall
(range −2.1 to −14.0%) and the magnitude of change did
not differ between groups (Table 2). Concomitantly, waist
circumference decreased by −7.3 ± 0.5 cm. Compared with
subjects’ baseline diet records, during the intervention total
caloric intake decreased by −559 ± 54 kcal/day, total fat
by −2.6 ± 0.7% of energy, saturated fat by −2.0 ± 0.5%
of energy, sodium by −578 ± 146 mg/day, and protein
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TABLE 1 | Demographic and clinical data at baseline.
NGT (n = 15) IGT (n = 24) T2D (n = 15) P
Age (yrs) 56 ± 2 57 ± 1 56 ± 2 0.88
Gender (M/F) 9/6 13/11 6/9 0.52
Body weight (kg) 96.4 ± 3.4 96.8 ± 2.6 97.8 ± 4.0 0.96
Body mass index (kg/m2) 32.0 ± 0.8 33.1 ± 0.8 33.6 ± 1.9 0.64
Waist circumference (cm) 110.3 ± 2.6 107.4 ± 2.2 106.7 ± 2.8 0.61
Waist: Hip ratio 0.96 ± 0.02 0.92 ± 0.02 0.91 ± 0.02 0.22
Exercise (min/day) 36 ± 8 31 ± 6 35 ± 9 0.86
Fasting glucose (mmol/L) 5.5 ± 0.1*** 5.6 ± 0.1*** 6.7 ± 0.2 <0.001
2-hour glucose (mmol/L) 6.5 ± 0.3***‡ 9.4 ± 0.2*** 13.2 ± 0.7 <0.001
Glucose AUC0−120(mmol · min · L
−1) 1035 ± 45***† 1167 ± 33*** 1489 ± 44 <0.001
Fasting insulin (mU/L) 13.8 ± 1.7 16.3 ± 1.2 18.5 ± 1.5 0.12
Insulin AUC0−120(mU · min · L
−1) 11761 ± 981 9606 ± 798 8819 ± 1104 0.12
HOMA-IR 3.56 ± 0.49** 4.14 ± 0.30* 5.47 ± 0.50 0.01
Matsuda ISI 2.68 [1.88, 3.49] 2.29 [1.88, 2.87] 1.93 [1.35, 2.48] 0.08
Insulinogenic index (mU insulin · mmol−1 glucose) 22.5 ± 3.1***† 15.9 ± 1.7* 9.3 ± 1.5 0.001
LDL-cholesterol (mmol/L) 3.5 ± 0.3 3.5 ± 0.2 3.4 ± 0.2 0.81
HDL-cholesterol (mmol/L) 1.23 ± 0.07 1.21 ± 0.04 1.20 ± 0.07 0.92
Triglycerides (mmol/L) 1.4 [1.2, 2.1] 1.3 [1.1, 2.0] 1.3 [1.2, 1.7] 0.71
Hs-CRP (mg/L) 2.5 [1.5, 2.9] 2.3 [1.2, 3.6] 1.7 [1.0, 4.6] 0.95
NEFA (mEq/L) 0.51 ± 0.05 0.54 ± 0.04 0.59 ± 0.05 0.52
Leptin (ng/ml) 10 [7, 23] 15 [9, 26] 17 [7, 37] 0.69
Systolic BP (mmHg) 129 ± 4 126 ± 3 134 ± 5 0.29
Diastolic BP (mmHg) 75 ± 2 71 ± 2 75 ± 3 0.35
Heart rate (bpm) 65 ± 2 62 ± 2 63 ± 2 0.72
Cardiac BRS (msec/mmHg) 10.2 [7.9, 16.1] 11.5 [7.3, 14.9] 11.9 [8.3, 13.7] 0.99
PRA (ng/ml/h) 0.88 [0.55, 1.32] 0.54 [0.32, 0.89] 0.61 [0.26, 1.17] 0.20
Values are mean± SEM or median [interquartile range]. AUC, area under the curve; BP, blood pressure; BRS, baroreflex sensitivity; HDL, high-density lipoprotein; HOMA-IR, homeostasis
model assessment-insulin resistance; hs-CRP, high-sensitivity C-reactive protein; ISI, insulin sensitivity index; LDL, low-density lipoprotein; NEFA, non-esterified fatty acids; PRA, plasma
renin activity. ***P < 0.001, **P < 0.01 and *P < 0.05 vs. T2D group;
†
P < 0.05 and
‡
P < 0.01 vs. IGT group.
intake increased by 3.9 ± 0.6% of energy (P all <0.001).
There were no significant between group differences in dietary
parameters. Time spent exercising increased by 14 ± 4 min/day
in the NGT (P = 0.04), 12 ± 5 min/day in the IGT
(p = 0.02), and by 0 ± 7 min/day in the T2D groups
(P = 0.94).
Glucose Metabolism and Insulin Action
Figure 1 shows comparative changes in glucose and insulin
parameters following HCD. The obese T2D group experienced
significantly greater reductions in fasting glucose, 2-h glucose
and glucose AUC0−120, compared with the NGT and IGT groups
(group effect, P all <0.001). Fasting insulin and the insulin
AUC0−120 were significantly reduced after HCD in all three
groups (P all <0.01), however the magnitude of change in
the latter was greater in the NGT group vs. IGT and T2D
groups (P both <0.05). The insulinogenic index decreased
in NGT and IGT groups, but increased in the T2D group
(group × time, P = 0.04). Matsuda ISI increased significantly in
all groups (P all <0.001) with the magnitude of change tending
to be greater in NGT and T2D group vs. IGT (P = 0.053,
Table 2).
Blood Chemistry
There were significant reductions in plasma leptin, LDL-
cholesterol, triglycerides, and hs-CRP after the HCD
intervention, with no significant group by time interactions
(Table 2). Plasma NEFA, HDL-cholesterol, and PRA were
unchanged in all three groups.
Sympathetic Neural Activity
Acceptable paired microneurographic recordings were obtained
in 43 subjects (12 NGT, 19 IGT, and 12 T2D). MSNA was
significantly attenuated when expressed as burst frequency or
burst incidence with no significant between group differences
(Figures 2A,B).
Arterial norepinephrine concentration decreased significantly
in each group (Figure 2C, P all ≤ 0.001) by −23 ± 6, −16 ±
4, and −25 ± 4% in NGT, IGT, and T2D groups respectively
(between group P = 0.39). Norepinephrine plasma clearance
was unchanged in all three groups. Calculated whole-body
norepinephrine spillover rate decreased in all groups, but the
magnitude of change did not differ (Figure 2D).
Subgroup analysis by baseline hyperinsulinemia (Figure 3)
showed that hyperinsulinemic subjects (baseline insulin
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TABLE 2 | Changes in selected anthropometric and clinical data after hypocaloric diet.
Parameter NGT (n = 15) IGT (n = 24) T2D (n = 15) Time effect (P) Time × Group (P)
ANTHROPOMETRICS
1 Body weight (kg) −7.2 ± 0.7*** −7.8 ± 0.5*** −7.9 ± 1.0*** <0.001 0.75
1 Body weight (%) −7.5 ± 0.8*** −8.1 ± 0.5*** −8.0 ± 0.9*** <0.001 0.79
1 Body mass index (kg/m2) −2.4 ± 0.2*** −2.7 ± 0.2*** −2.6 ± 0.3*** <0.001 0.62
1 Waist circumference (cm) −7.6 ± 1.2*** −7.3 ± 0.6*** −7.0 ± 1.1*** <0.001 0.92
1 Waist: hip ratio −0.03 ± 0.01** −0.03 ± 0.01*** −0.02 ± 0.01 <0.001 0.62
METABOLIC AND BIOCHEMICAL
1 Glucose AUC0−120 (mmol · min · L
−1) −94 ± 32*† −15 ± 22‡ −225 ± 49*** <0.001 <0.001
1 Fasting insulin (mU/L) −3.3 ± 0.7*** −3.6 ± 0.7*** −4.4 ± 1.2*** <0.001 0.72
1 HOMA-IR −0.99 ± 0.21** −1.01 ± 0.19*** −1.70 ± 0.47*** <0.001 0.17
1 Matsuda ISI 1.81 ± 0.63*** 0.65 ± 0.13*** 1.30 ± 0.33*** <0.001 0.053
1 Matsuda ISI (%) 60 ± 16# 30 ± 6 61 ± 13# <0.001 0.06
1 LDL-cholesterol (mmol/L) −0.3 ± 0.1* −0.2 ± 0.1* −0.3 ± 0.1* <0.001 0.91
1 HDL-cholesterol (mmol/L) −0.02 ± 0.05 0.05 ± 0.03 −0.03 ± 0.05 0.99 0.33
1 Triglycerides (mmol/L) −0.4 ± 0.2 −0.5 ± 0.1*** −0.4 ± 0.1*** <0.001 0.40
1 NEFA (mEq/L) −0.04 ± 0.04 −0.02 ± 0.03 −0.05 ± 0.05 0.11 0.81
1 Leptin (ng/ml) −5.1 ± 0.9*** −6.7 ± 1.1*** −9.2 ± 2.8*** <0.001 0.69
1 hs-CRP (mg/L) −0.5 ± 0.2** −0.9 ± 0.3*** −0.3 ± 0.3 <0.001 0.24
1 PRA (ng/ml/h) −0.36 ± 0.18 −0.01 ± 0.10 −0.17 ± 0.30 0.59 0.36
Values are mean ± SEM. ***P ≤ 0.001, **P ≤ 0.01 and *P < 0.05 vs. baseline;
†
P < 0.05 and
‡
P < 0.01 vs. T2D; #P < 0.05 vs. IGT.
AUC0−120, 13,374 ± 498 mU · min · L
−1) experienced
significantly greater reductions in insulin AUC0−120, arterial
norepinephrine concentration, whole-body norepinephrine
spillover rate, and heart rate than normoinsulinemic
counterparts (baseline insulin AUC0−120, 6598± 352 mU ·min ·
L−1), despite similar weight loss (−7.7 ± 0.6 and −7.6 ± 0.6 kg,
respectively). Hyperinsulinemic subjects had significantly lower
BRS at baseline compared with normoinsulinemic subjects (11.1
± 1.3 vs. 15.0± 1.7 ms/mmHg, P = 0.03).
Cardiovascular Parameters
Clinic systolic blood pressure decreased by −7 ± 2, −5 ± 2, and
−9 ± 3 mmHg in NGT, IGT, and T2D groups respectively (time
effect, P < 0.001; group effect, P = 0.46). Clinic diastolic blood
pressure decreased significantly only in the T2D group (time
effect, P < 0.01; group effect P = 0.09, Figure 2E). Spontaneous
BRSwas enhanced in all three groups (time effect P< 0.001), with
no significant differences between groups (Figure 2F).
Regression Analyses
Reduction in sympathetic neural parameters was not associated
with changes in body weight, body mass index, waist
circumference, glycemic indices, or dietary parameters. Stepwise
regression analyses of the pooled data set showed that reduction
in insulin AUC0−120 was independently associated with change
in arterial norepinephrine concentration, explaining 9% of the
variance (P = 0.03, Table 3). This relationship was stronger in
males, where 1 insulin AUC0−120 explained 49% of the variance
(P < 0.001) in norepinephrine levels following HCD. Change
in whole-body norepinephrine spillover rate was significantly
associated with changes in plasma leptin level and PRA, whilst
attenuation in MSNA related to improvement in BRS and
reduction in LDL-cholesterol (Table 3). Improvement in BRS
was most strongly correlated with reduction in triglyceride levels
(r =−0.36, P = 0.01).
DISCUSSION
In this study we sought to compare the benefits of equivalent
weight loss, achieved through HCD, on SNS activity in un-
medicated, matched obese subjects who were stratified according
to their glucose tolerance, and who are representative of
distinct metabolic sub-groups along the diabetes continuum.
In accordance with previously published data, we found that
T2D subjects experienced greater reductions in fasting and
post-OGTT glucose levels and an increase in insulinogenic
index compared with their non-diabetic counterparts (Solomon
et al., 2010). However, the greater improvement in glycemic
indices did not translate to any additive effect on spontaneous
cardiac BRS nor on sympathoinhibition. Indeed, weight loss
was associated with significant and similar attenuation in both
neurophysiological and biochemical measures of sympathetic
activity across the groups. To our knowledge, ours is the firsts
study to demonstrate that moderate weight loss attenuates
MSNA and whole-body norepinephrine spillover rate in
treatment naïve T2D subjects. Pooled regression analysis
indicated that reductions in hyperinsulinemia, gauged as
the insulin response during OGTT, leptin and PRA, and
enhancement of BRS were independently associated with
sympathoinhibition within the cohort. These findings are
elaborated below.
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FIGURE 1 | Comparative changes in glucose and insulin parameters. (A) Fasting plasma glucose: time effect, P < 0.001; time × group interaction, P < 0.001.
***P < 0.001 vs. NGT and IGT groups. (B) Two-hour plasma glucose following oral glucose tolerance test: time effect, P < 0.001; time × group interaction,
P < 0.001. ***P < 0.001 vs. NGT and IGT groups. (C) Insulinogenic index: time × group interaction, P = 0.04. *P < 0.05 vs. T2D group. (D) Plasma insulin area
under the curve during oral glucose tolerance test: time effect, P < 0.001; time × group interaction, P = 0.04. *P < 0.05 vs. IGT and T2D groups.
Only one other study has compared weight loss associated
improvements in autonomic function in different obese
subgroups. Casellini et al. (2016) measured time and frequency
domain analysis of heart rate variability before and after
surgical weight loss in non-diabetic, pre-diabetic, and T2D
subjects. They reported that changes in cardiac autonomic
function, representing both sympathetic and parasympathetic
components, were significantly greater in T2D subjects.
However, this study is not comparable to ours because of
differences in participants’ clinical status (their T2D subjects
had long-standing drug-treated diabetes and non-diabetic
subjects were normoinsulinemic); the mode and magnitude
of weight loss (four times greater than that attained in our
study); and the indirect quantification of cardiac autonomic
tone. In contrast, our NGT group was hyperinsulinemic and
we found no differentiation in sympathetic neural activity or
spontaneous cardiac BRS at baseline, nor in the response to
HCD, between our three groups. Previous cross-sectional studies
have shown higher MSNA and lower BRS in T2D subjects vs.
matched normoinsulinemic NGT subjects (Gerritsen et al.,
2000; Huggett et al., 2003). This discrepancy is likely explained
by the hyperinsulinemic status of our NGT group and our
findings need to be interpreted in this context. Furthermore,
categorization as NGT in our study was based only on 2-h
glucose concentration, thus some NGT subjects may have had
impaired fasting glucose, which could have influenced the results
by minimizing between-group differences. Albeit, a recent study
reported no differences in BRS between subjects categorized as
having isolated impaired fasting glucose vs. those with NGT (Wu
et al., 2014).
There is now ample clinical and experimental evidence
that links hyperinsulinemia to augmented central sympathetic
outflow (Anderson et al., 1991; Rahmouni et al., 2004).
Distinct central signaling pathways have been identified that
mediate insulin-induced regional sympathoactivation to skeletal
muscle, adipose tissue and the kidneys (Rahmouni et al., 2003,
2004). In the present study, reduction in hyperinsulinemia
was independently associated with attenuation in arterial
norepinephrine concentration, which concurs with our
previous findings in other cohorts (Straznicky et al., 2014).
This observation also concurs with the demonstration that
individuals with higher baseline plasma insulin derive the
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FIGURE 2 | Comparative changes in sympathetic neural and cardiovascular parameters. (A) Muscle sympathetic nerve activity (MSNA) expressed as burst
frequency: time effect, P < 0.001. (B) MSNA expressed as burst incidence: time effect, P < 0.001. (C) Arterial norepinephrine (NE) concentration: time effect,
P < 0.001. (D) Whole-body NE spillover rate: time effect, P < 0.001. (E) Clinic diastolic blood pressure (BP): time effect, P = 0.005; time × group interaction,
P = 0.09. (F) Spontaneous cardiac baroreflex sensitivity (BRS): time effect, P < 0.001.
greatest improvement in macrovascular and microvascular
endothelial function following weight loss (Bigornia et al.,
2013). Furthermore, post-hoc analyses in the Swedish Obese
Study indicated that higher baseline insulin concentration
was associated with a more favorable outcome of bariatric
surgery on cardiovascular events after a median follow-up of
15 years (Sjöström et al., 2012). Aside from its direct effects on
central sympathetic outflow, hyperinsulinemia secondary to
insulin resistance may also modulate BRS by both peripheral
and central mechanisms. Peripherally, insulin resistance
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FIGURE 3 | Comparative changes in sympathetic neural and cardiovascular parameters in normoinsulinemic and hyperinsulinemic subjects. (A) Insulin
area under the curve (AUC) during oral glucose tolerance test. (B) Arterial plasma norepinephrine (NE) concentration. (C) Whole-body NE spillover rate. (D) Muscle
sympathetic nerve activity (MSNA) burst frequency. (E) Heart rate. (F) Spontaneous cardiac baroreflex sensitivity (BRS). *P < 0.05, **P < 0.01, and ***P < 0.001 vs.
normoinsulinemic group. Normoinsulinemic: insulin AUC0−120 ≤ 9500 mU/min/L (n = 27); hyperinsulinemic: insulin AUC0−120 > 9500 mU/min/L (n = 27).
TABLE 3 | Stepwise regression analyses of changes in sympathetic neural parameters following hypocaloric diet.
Dependent variables Step Independent variables Std. coeff r2 P
1 Log NE (pg/ml) 1 1 Insulin AUC0−120 (mU/min/L) 0.30 0.09 0.03
1 Log NE spillover rate (ng/min) 1 1 Leptin (ng/ml) 0.33 0.13 0.01
2 1 PRA (ng/ml/h) 0.29 0.21 0.03
1 MSNA (bursts/min) 1 1 BRS (msec/mmHg) −0.31 0.15 0.046
2 1 LDL-C (mmol/L) 0.30 0.23 0.049
1 MSNA (bursts/100hb) 1 1 LDL-C (mmol/L) 0.33 0.11 0.04
Regression analyses were adjusted for age (years), change in body weight (kg) and change in exercise (min/day). MSNA, muscle sympathetic nerve activity; NE, norepinephrine.
and attendant pathophysiologies (glucotoxicity, lipotoxicity,
and inflammation) promote endothelial dysfunction, arterial
stiffening, and impaired baroreceptor afferent responses to
arterial wall stretch (Watkins et al., 2000; Grassi et al., 2005;
Kim et al., 2006). In the brain, insulin increases the gain of
baroreflex control of heart rate and MSNA (Pricher et al., 2008;
Young et al., 2010). Therefore, central insulin resistance which
is a characteristic of the metabolic syndrome, may reverse the
normal effects of brain insulin to support optimal baroreflex
control (Kaiyala et al., 2000). Consistent with these mechanisms,
hyperinsulinemic subjects had lower baseline BRS compared
with normoinsulinemic subjects in our study. It is of note that
the observed dichotomy of changes in insulinogenic index
between T2D and NGT subjects after HCD has been reported
before. Solomon et al. (2010) demonstrated improved insulin
secretion in T2D subjects following moderate dietary weight loss
vs. reversal of compensatory hyperinsulinemia in nondiabetic
individuals. Relief of extreme hyperglycemia (glucotoxicity) and
enhanced secretion of the incretin hormone, glucose-dependent
insulinotropic polypeptide, explained the improvement
in pancreatic β-cell function in T2D subjects in their
study.
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Other factors that predicted sympathoinhibition in our study
included reductions in plasma leptin, LDL-cholesterol, and
activity of the renin-angiotensin system. In addition to its classic
effects on appetite, the adipokine leptin is known to increase
regional sympathetic nerve activity to the kidneys, adrenal gland,
hindlimb, and adipose tissue in laboratory animals (Mark, 2013).
The evidence for leptin-induced sympathoexcitation in humans
is less strong, and is limited to correlative data, including our own
showing an association with renal norepinephrine spillover rate
in healthy men of differing adiposity (Eikelis et al., 2003) and the
fact that leptin deficiency states are associated with sympathetic
hypofunction (Ozata et al., 1999). Clinical leptin administration
studies have yielded equivocal results (Mackintosh and Hirsch,
2001; Machleidt et al., 2013). A bidirectional interaction between
the SNS and the renin-angiotensin-aldosterone system (RAAS)
has been long appreciated (Grassi, 2001). RAAS activation
in obesity has been attributed to increased synthesis of
angiotensinogen by visceral fat, renal compression, and increased
sympathetic outflows to the kidneys stimulating renin release.
Elevated plasma LDL-cholesterol concentration is an established
trigger for impairment of endothelial function and we have
previously demonstrated both elevated MSNA and diminished
endothelial function in young adults with hypercholesterolaemia
compared to normal controls (Lambert et al., 2013). In the
present study LDL-cholesterol decreased significantly in all three
groups, likely in response to the reduced saturated fat content of
the background diet which averaged −10 g per day, and changes
in LDL independently related to reduction in MSNA.
Our study has a number of limitations which need to be
noted. Firstly, it did not include a control arm, however we
have previously demonstrated the reproducibility of MSNA and
norepinephrine kinetics measurements in weight stable subjects
over a 3-month period (Straznicky et al., 2010). Moreover, any
effects of familiarization on sympathetic neural measurements
would have been similar across the groups. Secondly, we did
not assess body composition using a robust technique such as
dual energy x-ray absorptiometry, so the impact of changes
in fat depots on SNS parameters could not be determined.
Thirdly, the study does not distinguish the effects of weight loss
vs. negative energy balance from dietary restriction. Fourthly,
subject numbers were relatively small and we may not have
had adequate power to detect small differences between groups.
Finally, we did not have any robust measures of fitness in order
to ascertain whether changes in exercise habit contributed to
sympathoinhibition. Exercise diaries indicated that on average
our cohort walked 30 min per day at baseline, and that the
NGT and IGT groups increased their average walking times
by 12–14 min per day, whereas there were no increments
in the T2D group during the intervention. Aerobic exercise
has independent beneficial effects on SNS activity, endothelial
function, baroreflex modulation, and insulin sensitivity, which
may have contributed to our findings (Jennings et al., 1986).
Results of the CALERIE study indicate that at identical energy
deficit incorporation of exercise training with caloric restriction
augmented improvements in cardiac sympathovagal balance
compared to calorie restriction alone (deJonge et al., 2010).
In summary, our study demonstrates that moderate weight
loss following HCD significantly attenuates SNS activity in obese
subjects with diverse glycemic status. Concurrent reductions
in hyperinsulinemia, leptin, LDL-cholesterol, and RAS were
associated with the sympathoinhibition attained. These findings
are of clinical importance in the context that elevated SNS activity
contributes to the pathogenesis of hypertension, target organ
damage and adverse cardiovascular and metabolic outcomes
in both non-obese and obese populations (Masuo et al., 2003;
Flaa et al., 2008; Schlaich et al., 2009). Additional studies are
needed to address (1) the benefits of weight loss on autonomic
function in hypoinsulinemic individuals with T2D; (2) the length
of time that reduced sympathetic neural function is maintained
after weight loss; and (3) the relationship between glycemic
variability assessed by 24-h continuous monitoring and SNS
activity.
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